Researchers at ACS showed that the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types.
Thyme Care announced the close of a $95 million capital raise. With $55 million in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital.
